Skip to main content

Gastric Adenocarcinoma clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for
  • Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

    Sorry, in progress, not accepting new patients

    A study of Zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in participants with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why was this study being done? SPOTLIGHT was a new clinical study for adult participants who had any of advanced unresectable gastric or GEJ cancer - metastatic gastric or GEJ cancer. These types of cancers had a unique set of proteins (called Claudin 18.2). We may be able to use a treatment that targets the proteins to kill the cancer cells. For participants with one of the types of cancer listed above, mFOLFOX6 (a combination of three chemotherapies known as Oxaliplatin, Leucovorin, and Fluorouracil) was a current treatment option. This study was testing an experimental medicine called Zolbetuximab (IMAB362). Zolbetuximab attached itself to Claudin 18.2 on the cancer cells causing cancer cell death. Participants were assigned to one of two groups by chance and given either: Zolbetuximab with mFOLFOX6; or a placebo with mFOLFOX6. A placebo was a treatment that looks like the experimental medicine, but contained no medicine. The goal of the study was to find out if Zolbetuximab with mFOLFOX6 helped participants to live longer by stopping the cancer from getting worse.

    San Francisco, California and other locations

  • DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

    Sorry, in progress, not accepting new patients

    A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    San Francisco, California and other locations

Last updated: